Barrx Medical Inc. signed an exclusive distribution deal with Medico’s Hirata for its Halo gastrointestinal disease treatment system.
Osaka, Japan-based Medico’s Hirata, a medical product supplier, said it is well-positioned to make the Halo device the standard of care in Japan.
The Halo system uses radiofrequency ablation to treat pre-cancerous lesions of the esophagus and other chronic gastrointestinal diseases, according to a Barrx press release.
Japan has one of the highest concentrations of esophageal squamous cell cancers in the world, according to the Sunnyvale, Calif.-based developer of gastroenterological endoscopic devices.
"We are excited to partner with Medico’s Hirata in one of our most important markets worldwide. … We look forward to a long mutually beneficial business relationship," Barrx CEO Greg Barrett said in prepared remarks.